Some luster restored

Developers of matrix metalloproteinase inhibitors as a cancer therapy will have been heartened by the seal of approval given to this class of drugs by Bristol-Myers Squibb, one of the leading players in cancer therapy.

CRO (Cambridge, U.K.) immediately laid claim that the accord with BMS validates its own approach. However, British Biotech plc (LSE:BBG; BBIOY, Oxford, U.K.) is still believed to hold pole position in the MMPI anti-cancer field with marimastat, which is considered to be a broad spectrum product. The compound is in Phase III trials in patients with one of six types of solid tumor - gastric, glioblastoma, non-small cell lung cancer, ovarian, pancreatic, and small cell lung cancer...